Testing BBT001 given by drip in adults with chronic spontaneous urticaria
Tests BBT001 against placebo in adults with chronic spontaneous urticaria.
Key facts
- Who runs it
- Bambusa Therapeutics
- Where
- China10 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 48 people, planned
- Started
- 29 Jun 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 8 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- BBT001
- Placebo
- Record updated
- 22 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic spontaneous urticaria (long-lasting hives with no known trigger). They must still have symptoms while taking antihistamines.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Chronic spontaneous urticaria with a hive activity score (UAS7) of 16 or more. Weight no more than 125 kg (276 lb) at screening.
- Earlier treatment
- People must be taking stable daily doses of H1 antihistamines (H1-AH). Some groups are for people who have never had biologic drugs. Other groups (A2/A4) are for people who have had biologic drugs such as omalizumab or dupilumab, with the last dose at least 5 half-lives before the study starts.
Main reasons for not taking part
- Hives brought on by a specific trigger (inducible urticaria)
- Other diseases that can look like hives or swelling, such as urticarial vasculitis, erythema multiforme or cutaneous mastocytosis
- Other skin diseases that could affect the study results
- Past herpes simplex infection
- Blood tests at screening showing signs of infection
The registry criteria, word for word
Show the criterionShow less
Who cannot take part
- -
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase IIa, randomized, blinded, placebo controlled,Multiple-Ascending Dose study of BBT001 in adult patients with Chronic Spontaneous Urticaria.
The 8 groups in the trial
- Cohort A1:BBT001 (450mg biologic naive)Existing treatment, for comparison
A multiple ascending dose (MAD) of 450 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are naïve to biologic therapy.
Treatment: BBT001
- Cohort A1:Placebo (450mg biologic naive)Placebo, for comparison
A multiple ascending dose (MAD) of 450 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU)who are naïve to biologic therapy.
Treatment: Placebo
- Cohort A2:BBT001 (450mg biologic experienced)Existing treatment, for comparison
A multiple ascending dose (MAD) of 450 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are experienced to biologic therapy.
Treatment: BBT001
- Cohort A1:placebo (450mg biologic experienced)Placebo, for comparison
A multiple ascending dose (MAD) of 450 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are experienced to biologic therapy
Treatment: Placebo
- Cohort A3:BBT001 (900mg biologic naive)Existing treatment, for comparison
A multiple ascending dose (MAD) of 900 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are naïve to biologic therapy.
Treatment: BBT001
- Cohort A3:Placebo (900mg biologic naive)Placebo, for comparison
A multiple ascending dose (MAD) of 900 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are naïve to biologic therapy.
Treatment: Placebo
- Cohort A4:BBT001 (900mg biologic experienced)Existing treatment, for comparison
A multiple ascending dose (MAD) of 900 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are experienced to biologic therapy.
Treatment: BBT001
- Cohort A4:Placobo (900mg biologic experienced)Placebo, for comparison
A multiple ascending dose (MAD) of 900 mg BBT001 will be administered to patients with chronic spontaneous urticaria (CSU) who are experienced to biologic therapy.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Adult Patients With Chronic Spontaneous Urticaria.
- Plain-language title
- Testing BBT001 given by drip in adults with chronic spontaneous urticariaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07717905, who can take part
- Record updated
- 22 July 2026